Linaprazan is an experimental drug for the treatment of

gastroesophageal reflux disease Gastroesophageal reflux disease (GERD) or gastro-oesophageal reflux disease (GORD) is one of the upper gastrointestinal chronic diseases where stomach content persistently and regularly flows up into the esophagus, resulting in symptoms and/ ...

(GERD). Unlike the

proton-pump inhibitor Proton-pump inhibitors (PPIs) are a class of medications that cause a profound and prolonged reduction of stomach acid production. They do so by irreversibly inhibiting the stomach's H+/K+ ATPase proton pump. They are the most potent inhibitor ...

s (PPIs) which are typically used to treat GERD, linaprazan is a

potassium-competitive acid blocker Proton pump inhibitors (PPIs) block the gastric hydrogen potassium ATPase (H+/K+ ATPase) and inhibit gastric acid secretion. These drugs have emerged as the treatment of choice for acid-related diseases, including gastroesophageal reflux disease (G ...

(P-CAB). Linaprazan was developed by AstraZeneca, but it was not successful in clinical trials. The drug was then licensed to Cinclus Pharma, which is now investigating linaprazan glurate, a prodrug of linaprazan which is expected to have a longer

biological half-life Biological half-life (also known as elimination half-life, pharmacologic half-life) is the time taken for concentration of a biological substance (such as a medication) to decrease from its maximum concentration ( Cmax) to half of Cmax in the bl ...

than linaprazan itself. :

References

{{Proton-Pump Inhibitors Proton-pump inhibitors Imidazopyridines Secondary alcohols Ethanolamines Carboxamides